150 related articles for article (PubMed ID: 25993998)
1. Identification of a Dual Inhibitor of SRPK1 and CK2 That Attenuates Pathological Angiogenesis of Macular Degeneration in Mice.
Morooka S; Hoshina M; Kii I; Okabe T; Kojima H; Inoue N; Okuno Y; Denawa M; Yoshida S; Fukuhara J; Ninomiya K; Ikura T; Furuya T; Nagano T; Noda K; Ishida S; Hosoya T; Ito N; Yoshimura N; Hagiwara M
Mol Pharmacol; 2015 Aug; 88(2):316-25. PubMed ID: 25993998
[TBL] [Abstract][Full Text] [Related]
2. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD.
Gammons MV; Fedorov O; Ivison D; Du C; Clark T; Hopkins C; Hagiwara M; Dick AD; Cox R; Harper SJ; Hancox JC; Knapp S; Bates DO
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6052-62. PubMed ID: 23887803
[TBL] [Abstract][Full Text] [Related]
3. A novel class of selective CK2 inhibitors targeting its open hinge conformation.
Dalle Vedove A; Zonta F; Zanforlin E; Demitri N; Ribaudo G; Cazzanelli G; Ongaro A; Sarno S; Zagotto G; Battistutta R; Ruzzene M; Lolli G
Eur J Med Chem; 2020 Jun; 195():112267. PubMed ID: 32283296
[TBL] [Abstract][Full Text] [Related]
4. Specific inhibition of serine/arginine-rich protein kinase attenuates choroidal neovascularization.
Dong Z; Noda K; Kanda A; Fukuhara J; Ando R; Murata M; Saito W; Hagiwara M; Ishida S
Mol Vis; 2013; 19():536-43. PubMed ID: 23559848
[TBL] [Abstract][Full Text] [Related]
5. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.
Batson J; Toop HD; Redondo C; Babaei-Jadidi R; Chaikuad A; Wearmouth SF; Gibbons B; Allen C; Tallant C; Zhang J; Du C; Hancox JC; Hawtrey T; Da Rocha J; Griffith R; Knapp S; Bates DO; Morris JC
ACS Chem Biol; 2017 Mar; 12(3):825-832. PubMed ID: 28135068
[TBL] [Abstract][Full Text] [Related]
6. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity.
Gammons MV; Dick AD; Harper SJ; Bates DO
Invest Ophthalmol Vis Sci; 2013 Aug; 54(8):5797-806. PubMed ID: 23761094
[TBL] [Abstract][Full Text] [Related]
7. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.
Hatcher JM; Wu G; Zeng C; Zhu J; Meng F; Patel S; Wang W; Ficarro SB; Leggett AL; Powell CE; Marto JA; Zhang K; Ki Ngo JC; Fu XD; Zhang T; Gray NS
Cell Chem Biol; 2018 Apr; 25(4):460-470.e6. PubMed ID: 29478907
[TBL] [Abstract][Full Text] [Related]
8. Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340).
Siqueira RP; Barbosa Éde A; Polêto MD; Righetto GL; Seraphim TV; Salgado RL; Ferreira JG; Barros MV; de Oliveira LL; Laranjeira AB; Almeida MR; Júnior AS; Fietto JL; Kobarg J; de Oliveira EB; Teixeira RR; Borges JC; Yunes JA; Bressan GC
PLoS One; 2015; 10(8):e0134882. PubMed ID: 26244849
[TBL] [Abstract][Full Text] [Related]
9. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.
Palanki MS; Akiyama H; Campochiaro P; Cao J; Chow CP; Dellamary L; Doukas J; Fine R; Gritzen C; Hood JD; Hu S; Kachi S; Kang X; Klebansky B; Kousba A; Lohse D; Mak CC; Martin M; McPherson A; Pathak VP; Renick J; Soll R; Umeda N; Yee S; Yokoi K; Zeng B; Zhu H; Noronha G
J Med Chem; 2008 Mar; 51(6):1546-59. PubMed ID: 18311895
[TBL] [Abstract][Full Text] [Related]
10. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.
Oltean S; Gammons M; Hulse R; Hamdollah-Zadeh M; Mavrou A; Donaldson L; Salmon AH; Harper SJ; Ladomery MR; Bates DO
Biochem Soc Trans; 2012 Aug; 40(4):831-5. PubMed ID: 22817743
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
[TBL] [Abstract][Full Text] [Related]
12. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
Gammons MV; Lucas R; Dean R; Coupland SE; Oltean S; Bates DO
Br J Cancer; 2014 Jul; 111(3):477-85. PubMed ID: 25010863
[TBL] [Abstract][Full Text] [Related]
13. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.
Amin EM; Oltean S; Hua J; Gammons MV; Hamdollah-Zadeh M; Welsh GI; Cheung MK; Ni L; Kase S; Rennel ES; Symonds KE; Nowak DG; Royer-Pokora B; Saleem MA; Hagiwara M; Schumacher VA; Harper SJ; Hinton DR; Bates DO; Ladomery MR
Cancer Cell; 2011 Dec; 20(6):768-80. PubMed ID: 22172722
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor.
Kinose F; Roscilli G; Lamartina S; Anderson KD; Bonelli F; Spence SG; Ciliberto G; Vogt TF; Holder DJ; Toniatti C; Thut CJ
Mol Vis; 2005 May; 11():366-73. PubMed ID: 15951738
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
Sarno S; de Moliner E; Ruzzene M; Pagano MA; Battistutta R; Bain J; Fabbro D; Schoepfer J; Elliott M; Furet P; Meggio F; Zanotti G; Pinna LA
Biochem J; 2003 Sep; 374(Pt 3):639-46. PubMed ID: 12816539
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking.
Vangrevelinghe E; Zimmermann K; Schoepfer J; Portmann R; Fabbro D; Furet P
J Med Chem; 2003 Jun; 46(13):2656-62. PubMed ID: 12801229
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel and potent small molecule inhibitor of SRPK1: mechanism of dual inhibition of SRPK1 for the inhibition of cancer progression.
Chandra A; Ananda H; Singh N; Qamar I
Aging (Albany NY); 2020 Dec; 13(1):163-180. PubMed ID: 33291073
[TBL] [Abstract][Full Text] [Related]
18. The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration.
Hollanders K; Van Bergen T; Kindt N; Castermans K; Leysen D; Vandewalle E; Moons L; Stalmans I
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1335-48. PubMed ID: 25626969
[TBL] [Abstract][Full Text] [Related]
19. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
López-Ramos M; Prudent R; Moucadel V; Sautel CF; Barette C; Lafanechère L; Mouawad L; Grierson D; Schmidt F; Florent JC; Filippakopoulos P; Bullock AN; Knapp S; Reiser JB; Cochet C
FASEB J; 2010 Sep; 24(9):3171-85. PubMed ID: 20400536
[TBL] [Abstract][Full Text] [Related]
20. Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy.
Malhi NK; Allen CL; Stewart E; Horton KL; Riu F; Batson J; Amoaku W; Morris JC; Arkill KP; Bates DO
Am J Physiol Heart Circ Physiol; 2022 Jun; 322(6):H1014-H1027. PubMed ID: 35302878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
